Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vertex Advances Toward Telaprevir Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

The first Phase III results for the hepatitis C direct-acting antiviral give the firm reason to be confident.

You may also be interested in...



With Positive Boceprevir Data In Hand, Merck Prepares NDA Submission

The race to bring the first oral protease inhibitor to market for the treatment of hepatitis C shows no signs of abating. Merck announced positive data from two Phase III trials evaluating boceprevir Aug. 4, along with plans to initiate a rolling NDA submission and complete the filing by the end of the year. That puts boceprevir on about the same regulatory trajectory as Vertex/Johnson & Johnson's telaprevir, which Vertex has said it will file in the second half of the year

With Positive Boceprevir Data In Hand, Merck Prepares NDA Submission

The race to bring the first oral protease inhibitor to market for the treatment of hepatitis C shows no signs of abating. Merck announced positive data from two Phase III trials evaluating boceprevir Aug. 4, along with plans to initiate a rolling NDA submission and complete the filing by the end of the year. That puts boceprevir on about the same regulatory trajectory as Vertex/Johnson & Johnson's telaprevir, which Vertex has said it will file in the second half of the year

With Positive Boceprevir Data In Hand, Merck Prepares NDA Submission

Two Phase III trials evaluating the protease inhibitor in HCV met their primary endpoints but the real test is how boceprevir stacks up to Vertex's telaprevir.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel